Clinical Trials Browser

Phase 1 × Carcinoma × tislelizumab × Clear all

NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms